BioXcel Therapeutics (BTAI) Projected to Post Earnings on Tuesday

BioXcel Therapeutics (NASDAQ:BTAI) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect BioXcel Therapeutics to post earnings of ($4.36) per share and revenue of $0.72 million for the quarter.

BioXcel Therapeutics Stock Up 23.0 %

Shares of BioXcel Therapeutics stock opened at $3.37 on Monday. The stock has a market capitalization of $10.45 million, a price-to-earnings ratio of -0.10 and a beta of 0.89. BioXcel Therapeutics has a twelve month low of $1.72 and a twelve month high of $52.80. The company has a 50-day simple moving average of $4.38 and a two-hundred day simple moving average of $7.22.

Analyst Upgrades and Downgrades

BTAI has been the subject of several recent research reports. Bank of America reiterated an “underperform” rating and issued a $4.00 price target (down from $112.00) on shares of BioXcel Therapeutics in a research note on Tuesday, January 7th. HC Wainwright cut their target price on BioXcel Therapeutics from $80.00 to $48.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, Canaccord Genuity Group decreased their price target on BioXcel Therapeutics from $112.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, January 6th.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.